Andere Sprachen OptiNose, Inc.

Aktien

A2H5PR

US68404V1008

OPTN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 15.05.2024			% 5 Tage	% 1. Jan.
1,185 ^USD	+4,87 %		+13,94 %	-8,14 %

14.05.	Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024
14.05.	OptiNose, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	14.05.
OptiNose: Q1 Earnings Snapshot	14.05.
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights	14.05.
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Optinose Announces Reporting Date for First Quarter 2024 Financial Results	10.05.
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	09.05.
Optinose Announces $55 Million Registered Direct Offering	09.05.
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	25.04.
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million	25.04.
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	25.04.
Optinose, Inc. Announces Preliminary XHANCE Net Product Revenue Results for the First Quarter Ended March 31, 2024	25.04.
Optinose to Present at the Needham Virtual Healthcare Conference	04.04.
Sector Update: Health Care Stocks Steady Premarket Monday	18.03.
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	15.03.
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis	15.03.
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	15.03.
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	15.03.
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	14.03.
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	14.03.
OptiNose: Q4 Earnings Snapshot	07.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen OptiNose, Inc.

Aktien

A2H5PR

US68404V1008

OPTN

Andere Sprachen

Filter